STOCK TITAN

Palatin Appeals NYSE American Notice of Delisting

(Neutral)
(Neutral)
Tags

Palatin Technologies (NYSE American: PTN) has formally appealed NYSE Regulation's determination to delist its common stock after failing to meet stockholders' equity requirements by April 10, 2025. The company's stock will continue trading during the 60-to-90-day appeal process.

To regain compliance, Palatin is implementing a financial strengthening plan that includes:

  • Accelerating out-licensing discussions
  • Advancing equity financing negotiations
  • Exploring strategic funding opportunities

CEO Carl Spana expressed confidence in the company's ability to address listing requirements, though success of the appeal cannot be guaranteed. The final decision on whether PTN remains listed will be determined by the NYSE Listings Qualifications Panel.

Loading...
Loading translation...

Positive

  • Stock continues trading during appeal process
  • Company actively pursuing multiple financial strengthening initiatives

Negative

  • Failed to meet NYSE American stockholders' equity requirements
  • Risk of delisting from NYSE American exchange
  • Maximum 18-month compliance period expired without meeting requirements
  • No guarantee of successful appeal outcome

News Market Reaction – PTN

+15.39%
+15.39% Session move

In the trading session that priced this news, PTN gained 15.39%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Company working aggressively to regain compliance
  • Common stock to continue to trade on NYSE American during the appeal process

CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to delist its common stock.

NYSE Regulation determined the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii), related to stockholders' equity requirements, by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025.

Palatin's common stock will continue to trade on the NYSE American during the appeal process, which is expected to last 60-to-90-days. A final decision from the NYSE Listings Qualifications Panel will determine whether the stock remains listed or is delisted.

Palatin is actively implementing a plan to strengthen its financial position and regain compliance, including:

  • Accelerating out-licensing discussions across key development programs
  • Advancing equity financing negotiations
  • Exploring strategic funding opportunities

"We are moving quickly and deliberately to address the listing requirements," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "We believe the actions underway can restore compliance and create a stronger foundation for growth."

There can be no assurance the appeal will be successful. However, the Company is optimistic it will meet the listing requirement and remains committed to delivering value for its shareholders.  

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the Company's appeal of the delisting determination or the Company's expectation that it may be able to regain compliance, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.

Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-appeals-nyse-american-notice-of-delisting-302427341.html

SOURCE Palatin Technologies, Inc.

FAQ

Why is Palatin Technologies (PTN) facing delisting from NYSE American?

PTN failed to meet stockholders' equity requirements under Sections 1003(a)(i), (ii) and (iii) by the end of its 18-month compliance period on April 10, 2025.

How long will PTN stock continue trading during the NYSE American appeal process?

PTN stock will continue trading during the appeal process, which is expected to last 60-to-90 days.

What steps is Palatin taking to regain NYSE American compliance in 2025?

Palatin is accelerating out-licensing discussions, advancing equity financing negotiations, and exploring strategic funding opportunities to strengthen its financial position.

When will the final decision on PTN's NYSE American listing status be made?

The final decision will be made by the NYSE Listings Qualifications Panel after the 60-to-90-day appeal process.